Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation
Ben A. Croker(Boston Children's Hospital), Andrew W. Roberts(The Royal Melbourne Hospital)
Cited by 31
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
|New England Journal of Medicine|2018|429